Arcturus Therapeutics Holdings Inc. Quarterly Operating Income (Loss) in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q3 2024.
  • Arcturus Therapeutics Holdings Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$10.7M, a 44.4% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$80.5M, a 231% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2023 was -$78.2M, a 742% decline from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2022 was $12.2M.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2021 was -$203M, a 184% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$80.5M -$10.7M +$8.58M +44.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$89.1M -$21.1M +$34.2M +61.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$123M -$30.4M -$45.2M -306% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$78.2M -$18.3M -$140M -115% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $61.5M -$19.3M +$17.5M +47.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $44M -$55.4M -$33.3M -151% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $77.3M $14.8M +$65.1M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $12.2M $121M +$159M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$147M -$36.8M +$17M +31.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$164M -$22.1M +$31.6M +58.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$196M -$50.4M +$7.29M +12.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$203M -$37.6M -$6.56M -21.1% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$196M -$53.8M -$32.9M -157% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$163M -$53.7M -$43.7M -435% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$120M -$57.7M -$48.2M -509% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$71.5M -$31.1M -$20.3M -187% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$51.3M -$20.9M -$13.3M -175% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$37.9M -$10M -$9.47M -1656% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$28.5M -$9.46M -$2.95M -45.4% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$25.5M -$10.8M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$7.62M -$3.26M -74.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$572K +$9.5M +94.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$6.51M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q3 2018 -$4.36M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$10.1M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.